← Back to Search

Hsp90 Inhibitor

Gamitrinib for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the safety of gamitrinib, a new drug for advanced cancer patients. Gamitrinib works by blocking a protein that helps cancer cells survive. The study aims to find the best dose and see how well it works.

Eligible Conditions
  • Solid Tumors
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine the MTD and/or RP2D of gamitrinib when administered once weekly.
Secondary study objectives
Assess the pharmacodynamic effects of gamitrinib
Document any anti-tumor activity of single agent gamitrinib
Evaluate the overall safety profile of intravenously administered single-agent gamitrinib
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

7Treatment groups
Experimental Treatment
Group I: Dose 6Experimental Treatment1 Intervention
Accelerated Phase: 320 mg Standard Phase: 85 mg
Group II: Dose 5Experimental Treatment1 Intervention
Accelerated Phase: 160 mg Standard Phase: 65 mg
Group III: Dose 4Experimental Treatment1 Intervention
Accelerated Phase: 80 mg Standard Phase: 50 mg
Group IV: Dose 3Experimental Treatment1 Intervention
Accelerated Phase: 40 mg Standard Phase: 35 mg
Group V: Dose 2Experimental Treatment1 Intervention
Accelerated Phase: 20 mg Standard Phase: 20 mg
Group VI: Dose 1Experimental Treatment1 Intervention
Accelerated Phase: 10 mg Standard Phase: 10 mg
Group VII: Dose -1Experimental Treatment1 Intervention
Accelerated Phase: - Standard Phase: 5 mg

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,906 Previous Clinical Trials
41,011,990 Total Patients Enrolled
1,405 Trials studying Lymphoma
382,902 Patients Enrolled for Lymphoma
Fox Chase Cancer CenterLead Sponsor
234 Previous Clinical Trials
39,331 Total Patients Enrolled
14 Trials studying Lymphoma
143 Patients Enrolled for Lymphoma
National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,590 Total Patients Enrolled
27 Trials studying Lymphoma
12,954 Patients Enrolled for Lymphoma
~15 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top